Patients who are positive for the interleukin-1 (IL-1)

are at increased risk for severe periodontal disease.

have a decreased inflammatory response in the presence of bacteria.

are more likely to respond favourably to periodontal therapy.

have decreased bacterial pathogens associated with active periodontal disease.